Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vertex's Telaprevir Slides By Advisory Committee, But Panelists Want Limits On Some Patients

This article was originally published in The Pink Sheet Daily

Executive Summary

While the committee unanimously endorsed the protease inhibitor for approval, some panelists question whether there is sufficient data to support response-guided therapy for prior-relapse patients.
Advertisement

Related Content

Incivek Black Box Creates Fallout Risk For Vertex, FDA On Rash-related Fatalities
FDA Must Decide How To Handle Subgroups In Labeling For Boceprevir, Telaprevir
FDA Must Decide How To Handle Subgroups In Labeling For Boceprevir, Telaprevir
Post Panels, Telaprevir And Boceprevir Now Face FDA's Risk Management Review
Post Panels, Telaprevir And Boceprevir Now Face FDA's Risk Management Review
FDA May Grant Advantages For Vertex's Telaprevir Over Merck's Boceprevir
FDA May Grant Advantages For Vertex's Telaprevir Over Merck's Boceprevir

Topics

Advertisement
UsernamePublicRestriction

Register

PS072171

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel